Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab + pertuzumab + docetaxel as neoadjuvant therapy for HER2-positive breast cancer (single-arm phase II)
ChiCTR2300068725Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inetetamab in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Pathological complete response rate after neoadjuvant chemotherapy (pCR). Planned start May 2022; status: not yet recruiting.
02
Drugs
inetetamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300068725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068725.